AGORACOM News Flash

AGORACOM WIRE - WEDNESDAY MAY 30TH, 2012

GOLDEN HOPE MINES (TSXV:GNH) Confirms High Grade Intersection of 64.1 g/t Au (Gold) over 1m Read More

The screen metallic analysis returned 82 g/t Au for an average grade of 93.5 g/t Au.
Two additional fire assays on the original pulp done prior to the screen metallic analyses returned 0.22 g/t Au and 0.12 g/t Au for an average fire assay grade of 0.41 g/t Au. The weighted average of all the fire assays and screen metallic assays from this 1-metre section in hole BD2011-184 is 64.1 g/t Au.

Sonomax® eers™ Custom Earbuds Announces Sponsorship of MUTEK 2012

Mutek provides an essential platform for 150 performers to showcase forward-thinking electronic music programming and new media to more than 25,000 attendees
Read Full Press Release; Read Why Sonomax?
Jump Into Active Discussion Forum
*Sponsor*

CONTINENTAL ENERGY Geothermal Energy Project Receives US$ 11.5 Million Grant Read More * Client

AGORACOM Launches Graphite Stocks Blog

Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure

posted on Apr 08, 08 05:01AM

Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure

MONTREAL, Apr 8, 2008 -- Haemacure Corporation (TSX:HAE), a specialty bio-therapeutics company developing high-value human therapeutic proteins for commercialization, will hold its Annual General and Special Meeting of Shareholders on:

Mr. Joseph Galli, Chairman & CEO of Haemacure, will report on Haemacure's projects, recent developments and future outlook. Mr. Galli will also present an overview of the current clinical programs for Haemacure's proprietary fibrin sealant and hemostatic agent product candidates, construction of the Company's new manufacturing facility and growth potential.

Live Webcast

For those who are unable to attend in person, Haemacure will simultaneously host a live webcast with slides of Mr. Galli's presentation at http://events.snwebcastcenter.com/haemacure/20080409/

About Haemacure Corporation

Haemacure Corporation is a specialty bio-therapeutics company developing high-value human therapeutic proteins for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical haemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a human-derived fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is human thrombin, a component of its fibrin sealant, now in preclinical stage. Both candidates have applications in the expanding bio-surgical market. Follow-on development will focus on surgical haemostats, wound management, drug delivery, regenerative medicine, adhesion prevention and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one of its two plasma fractions and seeks to advance these specialty proteins and enzymes through partnerships with pharmaceutical and biotechnology companies.